TradingPro, funny that you used golf analogy - Kaplan Meier estimate with Log-Rank test is very much like analysing a golf game hole by hole. Kaplan Meier describes the events during the course and Log-Rank test sums up the score event by event and in this case came up with the clear winner - Brilacidin.
However, you are correct in pointing out that I can only guess what the censors stand for and or what happened in OM duration study - besides concurring with IPIX that the duration study results are non-informative.
But I can say with mathematical certainty that only one censor had some (near infinitesimal) effect on the outcome of OM incidence study, which is unassailable affirmation that censoring WAS NOT USED to manipulate the outcome.
And that should be good news to any long side investor - Log-Rank provided confirmed clean hazard ratio of 0.45 favoring Brilacidin over placebo.